CRDL Latest Press Releases

-- April 14, 2026 --

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart Newsfile 7:27 AM

-- April 1, 2026 --

Cardiol Therapeutics Announces Year-End 2025 Update on Operations Newsfile 7:27 AM

-- February 25, 2026 --

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference Newsfile 7:27 AM

-- February 10, 2026 --

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure Newsfile 7:27 AM

-- January 23, 2026 --

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million Newsfile 9:16 AM

-- January 16, 2026 --

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million Newsfile 8:46 AM

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million Newsfile 8:42 AM

-- January 13, 2026 --

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Newsfile 7:27 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software